Skip to Content
Merck
  • Modeling retinitis pigmentosa through patient-derived retinal organoids.

Modeling retinitis pigmentosa through patient-derived retinal organoids.

STAR protocols (2021-04-27)
Yan-Ping Li, Wen-Li Deng, Zi-Bing Jin
ABSTRACT

Human-induced pluripotent stem cells (hiPSCs) can be differentiated into well-structured retinal organoids. In this protocol, we successfully established 3D retinae from patient-derived hiPSCs and built the retinitis pigmentosa model in vitro. Moreover, mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene was corrected by CRISPR-Cas9 gene editing, which rescued the structure and function of the 3D retinae. For complete details on the use and execution of this protocol, please refer to Deng et al. (2018).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
G 418 disulfate salt, suitable for plant cell culture, BioReagent
Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sigma-Aldrich
Monoclonal Anti-Opsin antibody produced in mouse, clone RET-P1, ascites fluid
Sigma-Aldrich
1-Thioglycerol, liquid, BioReagent, suitable for cell culture, ≥97% (titration)
Sigma-Aldrich
MEM Non-essential Amino Acid Solution (100×), without L-glutamine, liquid, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Anti-Recoverin Antibody, serum, Chemicon®
Roche
DNase I, from bovine pancreas
Sigma-Aldrich
Anti-Opsin Antibody, Red/Green, Chemicon®, from rabbit